US Cancer Vaccine Market Sales Revenue Opportunity Report 2018

Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body’s natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer.

Download Report:

https://www.kuickresearch.com/report-US-Cancer-Vaccine-Market-Outlook-2018.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"US Cancer Vaccine Market Outlook 2018" Table of Contents

1. US Cancer Incidence & Prevalence
1.1 Leading Cancer Incidence
1.2 Incidence by State
1.3 Incidence by Gender
1.4 Incidence by Age Group

2. US Cancer Vaccine Market Outlook
2.1 Cancer Vaccine Market Overview
2.2 Therapeutic & Prophylactic Vaccines Market
2.3 Cancer Vaccine Pricing & Reimbursement Policy
2.4 Cancer Vaccine with Orphan Status
2.5 Cancer Research Funding & Grants

3. US Cancer Vaccine Market Dynamics
3.1 Favorable Market Drivers
3.2 Challenges to be Resolved
3.3 Future Growth Opportunities

4. US Cancer Vaccine Pipeline by Indication
4.1 Breast Cancer
4.2 Bladder Cancer
4.3 Colorectal Cancer
4.4 Endometrial Cancer
4.5 Renal Cancer
4.6 Leukaemia
4.7 Lung Cancer
4.8 Skin Cancer
4.9 Non-Hodgkin Lymphoma
4.10 Pancreatic Cancer

5. US Cancer Vaccine Pipeline by Clinical Phase
5.1 In Development Phase: Research till Phase III
5.2 Marketed Cancer Vaccines

6. US Cancer Vaccine Market Regulations
6.1 Considerations for Both Early and Late Phase Clinical Trials
6.1.1 Patient Population
6.1.2 Monitoring The Immune Response
6.1.3 Biomarkers As Evidence Of Efficacy
6.1.4 Adjuvants Used To Stimulate Immune Response
6.1.5 Multi-Antigen Vaccines
6.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines
6.1.7 Concomitant And Subsequent Therapies
6.2 Considerations for Early Phase Clinical Trials
6.2.1 Starting Dose And Dosing Schedule
6.2.2 Booster And Maintenance Therapy
6.2.3 Dose Escalation
6.2.4 Single-Arm Versus Randomized Phase 2 Trials In Early Development
6.3 Considerations For Late Phase Clinical Trials
6.3.1 Safety Profile From Early Phase Clinical Trials
6.3.2 Endpoints
6.3.3 Statistical Issues
6.3.4 Control Issues
6.3.5 Delayed Vaccine Effect
6.3.6 Autologous Vaccine Trials
6.3.7 Accelerated Approval Regulations

7. Competitive Landscape: Business Overview & Vaccine Pipeline
7.1 Merck & Co.
7.2 GSK
7.3 Dendreon
7.4 Aduro BioTech
7.5 Antigen Express
7.6 Bavarian Nordic
7.7 Celldex Therapeutics
7.8 Oxford BioMedica
7.9 Galena Biopharma

Figure 2-1: US Cancer Vaccine Market (US$ Billion), 2012-2018
Figure 2-2: US Share in Global Cancer Vaccines Market (%), 2013 & 2018
Figure 2-3: US Vaccine Markey by Therapeutic & Prophylactic Vaccines, 2012 & 2018
Figure 2-4: US Prophylactic Cancer Vaccines Market, (US$ Billion), 2012-2018
Figure 2-5: US Therapeutic Cancer Vaccines Market, (US$ Billion), 2012-2018

Figure 4-1: US Cancer Vaccine Pipeline by Indication (%)
Figure 4-2: US Cancer Vaccine Pipeline by Indication (Number of Vaccines)

Figure 4-3: US Breast Cancer Vaccine Pipeline by Phase (Number of Vaccines)
Figure 4-4: US Bladder Cancer Vaccine Pipeline by Phase (Number of Vaccines)
Figure 4-5: US Colorectal Cancer Vaccine Pipeline by Phase (Number of Vaccines)
Figure 4-6: US Endometrial Cancer Vaccine Pipeline by Phase (Number of Vaccines)
Figure 4-7: US Renal Cancer Vaccine Pipeline by Phase (Number of Vaccines)
Figure 4-8: US Leukemia Cancer Vaccine Pipeline by Phase (Number of Vaccines)
Figure 4-9: US Lung Cancer Vaccine Pipeline by Phase (Number of Vaccines)
Figure 4-10: US Skin Cancer Vaccine Pipeline by Phase (Number of Vaccines)
Figure 4-11: US Non-Hodgkin Lymphoma Vaccine Pipeline by Phase (Number of Vaccines)
Figure 4-12: US Pancreatic Cancer Vaccine Pipeline by Phase (Number of Vaccines)

Figure 5-1: US Cancer Vaccine Pipeline by Clinical Phase (%)
Figure 5-2: US Cancer Vaccine Pipeline by Clinical Phase (Number of Trials)

List of Tables

Table 1-1: Estimated Number of New Cases for Selected Cancers by State, US, 2013
Table 1-2: Estimated Number of Deaths for Selected Cancers by State, US, 2013
Table 1-3: Estimated Number of New Cancer Cases and Deaths by Gender, US, 2013
Table 1-4: Estimated New Cancer Cases by Age (years), 2013
Table 1-5: Estimated Cancer Deaths by Age (years), 2013
Table 2-1: US Orphan Designated Cancer Vaccines
Table 2-2: Spending on Cancer Research (US$ Million), 2010-2012
Table 2-3: Grants for Cancer Research (US$), 2013
Table 2-4: Grants for Cancer Research by States (US$), 2013
Table 2-5: Cancer Funding by Area of Research (US$)
Table 5-1: Marketed Cancer Vaccines: Indication & Brand Name
Table 7-1: Merck Cancer Vaccine Pipeline
Table 7-2: GSK Cancer Vaccine Pipeline
Table 7-3: Dendreon Corporation Cancer Vaccine Pipeline
Table 7-4: Aduro BioTech Cancer Vaccine Pipeline
Table 7-5: Aduro BioTech Cancer Immunotherapies
Table 7-6: Antigen Express Cancer Vaccine Pipeline
Table 7-7: Bavarian Nordic Cancer Vaccine Pipeline
Table 7-8: Celldex Therapeutics Cancer Vaccine Pipeline
Table 7-9: Oxford BioMedica Cancer Vaccine Pipeline
Table 7-10: Galena Biopharma Cancer Vaccine Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.